Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT06956170
- Locations
- 🇯🇵
GSK Investigational Site, Hokkaido, Japan
🇯🇵GSK Investigation Site, Fukushima City, Fukushima-Ken, Japan
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT06953960
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: FDG-Positron Emission Tomography
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT06948084
A Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06768489
- Locations
- 🇦🇺
Monash Medical Centre, Clayton, Australia
🇳🇱VU Medisch Centrum, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT06742138
Pomalidomide As an Immune-enhancing Agent for the Control of HIV
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 32
- Registration Number
- NCT06660498
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Australia
🇩🇰Aarhus University Hospital, Aarhus, Denmark
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 440
- Registration Number
- NCT06615479
- Locations
- 🇺🇸
Local Institution - 0071, Birmingham, Alabama, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸Local Institution - 0130, Miami, Florida, United States
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 43
- Registration Number
- NCT06554561
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06508983
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing GoBoard Boren Hospital, Beijing, China
🇨🇳Fu Xing Hospital, Capital Medical University, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.